Respiratory Medicine and Research最新文献

{"title":"Real-world comparison of chemo-immunotherapy and chemotherapy alone in the treatment of extensive-stage small-cell lung cancer","authors":"D. Lamy ,&nbsp;P. Mouillot ,&nbsp;A. Mariet ,&nbsp;R. Barnestein ,&nbsp;F. Quilot ,&nbsp;C. Fraisse ,&nbsp;F. Ghiringhelli ,&nbsp;P. Bonniaud ,&nbsp;A. Zouak ,&nbsp;P. Foucher","doi":"10.1016/j.resmer.2024.101125","DOIUrl":"10.1016/j.resmer.2024.101125","url":null,"abstract":"<div><h3>Introduction</h3><p>Small cell lung cancer (SCLC) is a high-grade neuroendocrine carcinoma responsible for 200,000 deaths per year worldwide. Platinum-etoposide-based chemotherapy has been the standard of treatment for the past 40 years, with an overall survival of 10 months. Since 2019, the addition of immunotherapy (atezolizumab or durvalumab) to chemotherapy has become the standard of care for first-line treatment of extensive-stage SCLC following the demonstration of an improvement in overall survival in phase 3 studies. We aimed to evaluate the efficacy and safety of chemo-immunotherapy compared with chemotherapy alone in a “real-world” setting.</p></div><div><h3>Methods</h3><p>Retrospective observational study including patients undergoing first-line treatment for extensive-stage SCLC between 2014 and 2022. We separated the study population into two arms (chemo-immunotherapy/chemotherapy). For each arm, progression-free survival (PFS), overall survival (OS) and serious side effects were collected. Associations between treatments and survival outcomes were adjusted for potential confounders. Consolidative palliative thoracic radiotherapy was introduced in the models as a time-dependent variable.</p></div><div><h3>Results</h3><p>A total of 118 patients with a median age of 63 years were included. 65.2 % of patients were performance status 0 or 1. In univariate analysis, PFS and OS were not significantly different between the chemo-immunotherapy and chemotherapy alone groups (<em>p</em> = 0.70 and 0.24 respectively). In multivariate analysis, the addition of immunotherapy to chemotherapy was not significantly associated with better PFS (HR 0.76, IC (0.49 – 1.19), <em>p</em> = 0.23), but it was significantly associated with better OS (HR 0.61, IC (0.38 – 0.98), <em>p</em> = 0.04). Consolidative palliative thoracic radiotherapy (time-dependent variable), when applied (almost only in the chemotherapy alone group), was significantly associated with better PFS and OS.</p></div><div><h3>Discussion</h3><p>In this real-world study, chemo-immunotherapy was associated with slightly better OS compared to chemotherapy alone as a first-line treatment in ES-SCLC patients in multivariate analysis, which is not explained by a benefit in PFS. However, consolidative palliative thoracic radiotherapy seems to be significantly associated with better OS and PFS, suggesting that we should also consider using it in patients receiving chemo-immunotherapy.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"86 ","pages":"Article 101125"},"PeriodicalIF":2.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590041224000412/pdfft?md5=6163e4bd3e4705c895951a02b4a7c251&pid=1-s2.0-S2590041224000412-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141701672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fast pleurodesis combining talc poudrage and indwelling pleural catheter for the management of recurrent malignant pleural effusions","authors":"Jean-Baptiste Lovato ,&nbsp;Sophie Laroumagne ,&nbsp;Julie Tronchetti ,&nbsp;Ngoc Anh Thu Nguyen ,&nbsp;Hervé Dutau ,&nbsp;Philippe Astoul","doi":"10.1016/j.resmer.2024.101124","DOIUrl":"10.1016/j.resmer.2024.101124","url":null,"abstract":"<div><h3>Background and objectives</h3><p>Malignant pleural effusions (MPE) are a frequent and major turning point in neoplastic disease usually leading to poor life expectancy. Improve quality of life and relieve the dyspnea are the main objectives in this palliative care setting. This can be achieved by the placement of an indwelling catheter (IPC) or talc pleurodesis ideally performed by thoracoscopy route (talc poudrage). Beside to misidentify a trapped-lung, the latter requires a prolonged hospital stay and the IPC placement does not allow a high pleurodesis rate. To overcome these drawbacks, a combination of both technique could be proposed for the management of recurrent malignant pleural effusions. Safety and efficacy of this pragmatic approach are reported.</p></div><div><h3>Methods</h3><p>Consecutive patients who have been managed for recurrent MPE by a combination of talc poudrage for pleural symphysis by thoracoscopy route ending with the insertion of IPC using the same thoracic point of entry. Demographic data, hospital length of stay (LOS), procedural-related complications, patients’ quality of life (QoL) and success of pleurodesis were collected. Patients were followed-up for 6 months.</p></div><div><h3>Results</h3><p>The data of twenty-five consecutive patients undergoing the procedure were analyzed. Successful pleurodesis was obtained for 14/25 patients (66 %) at one month, 17/20 patients (85 %) at 3 months and 13/15 patients (86 %) at 6 months respectively. On average, the hospital LOS after the procedure was 3.24 days (IQR 1–4) with a median of 1 day. A prolonged hospitalization (&gt;1 day) was never due to the procedure except for one patient (pneumothorax). No IPC related infection or procedure related deaths were noted.</p></div><div><h3>Conclusion</h3><p>Among patients with recurrent MPE, the combination of talc poudrage symphysis by thoracoscopy route and IPC placement on the same time results in a shortened hospital LOS and higher rate of pleurodesis. Further randomized clinical trials are needed to confirm these results.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"86 ","pages":"Article 101124"},"PeriodicalIF":2.2,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590041224000400/pdfft?md5=8a539327bdc3737de1953cd936680db1&pid=1-s2.0-S2590041224000400-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141538708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evidence and unresolved questions in pulmonary hypertension: Insights from the 5th French Pulmonary Hypertension Network Meeting","authors":"Athénaïs Boucly ,&nbsp;Laurent Bertoletti ,&nbsp;Charles Fauvel ,&nbsp;Mélanie Gallant Dewavrin ,&nbsp;Christian Gerges ,&nbsp;Julien Grynblat ,&nbsp;Christophe Guignabert ,&nbsp;Sébastien Hascoet ,&nbsp;Xavier Jaïs ,&nbsp;Etienne-Marie Jutant ,&nbsp;Nicolas Lamblin ,&nbsp;Olivier Meyrignac ,&nbsp;Marianne Riou ,&nbsp;Laurent Savale ,&nbsp;Cécile Tromeur ,&nbsp;Ségolène Turquier ,&nbsp;Simon Valentin ,&nbsp;Gérald Simonneau ,&nbsp;Marc Humbert ,&nbsp;Olivier Sitbon ,&nbsp;David Montani","doi":"10.1016/j.resmer.2024.101123","DOIUrl":"10.1016/j.resmer.2024.101123","url":null,"abstract":"<div><p>Pulmonary hypertension (PH) continues to present significant challenges to the medical community, both in terms of diagnosis and treatment. The advent of the updated 2022 European Society of Cardiology (ESC) and European Respiratory Society (ERS) guidelines has introduced pivotal changes that reflect the rapidly advancing understanding of this complex disease. These changes include a revised definition of PH, updates to the classification system, and treatment algorithm. While these guidelines offer a critical framework for the management of PH, they have also sparked new discussions and questions. The 5th French Pulmonary Hypertension Network Meeting (Le Kremlin-Bicêtre, France, 2023), addressed these emergent questions and fostering a deeper understanding of the disease's multifaceted nature. These discussions were not limited to theoretical advancements but extended into the practical realms of patient management, highlighting the challenges and opportunities in applying the latest guidelines to clinical practice.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"86 ","pages":"Article 101123"},"PeriodicalIF":2.2,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141555676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The challenges of identifying pulmonary embolism in patients hospitalized for exacerbations of COPD","authors":"Rufang Li ,&nbsp;Jie Zeng ,&nbsp;DanXiong Sun,&nbsp;Dengyuan Li","doi":"10.1016/j.resmer.2024.101122","DOIUrl":"10.1016/j.resmer.2024.101122","url":null,"abstract":"<div><h3>Background</h3><p>Chronic obstructive pulmonary disease (COPD) is associated with airflow obstruction that threatens global health. During the hospitalization of patients with acute exacerbations of COPD (AECOPD), the high prevalence of pulmonary embolism (PE) seriously affects the prognosis of disease. This study aims to assess the differences in clinical data between patients with AECOPD and patients with AECOPD-PE, and to identify the relevant factors of PE.</p></div><div><h3>Methods</h3><p>We performed a retrospective case-control study in AECOPD patients between January 2018 and December 2021. Due to suspected PE, all patients underwent radiological examination. Patients without PE were included as controls. Clinical data and laboratory tests were recorded. Univariate analysis and multivariate logistic regression analysis were used to investigate the independent predictors of PE. Receiver operating characteristics (ROC) curves was performed to evaluate the effect of risk factors on PE prediction.</p></div><div><h3>Results</h3><p>A total of 191 patients were included for analysis, divided into the AECOPD group (96 cases) and AECOPD-PE group (95 cases). No statistic differences were detected in demographic characteristics between patients with AECOPD and patients with AECOPD and PE. Average PO₂ and PCO₂ levels, lung function, and Echocardiographic indicator were not associated with PE. The concentration of D-dimer, the proportion of simplified wells score ≥ 2, and the incidence rate of lower extremity deep vein thrombosis (DVT) remarkably increased in AECOPD-PE group than AECOPD individuals. At multivariate analysis, the above three indicators were closely relevant to the occurrence of PE. The AUC value for D-dimer combined with lower extremity DVT and Simplified Wells Score was 0.729.</p></div><div><h3>Conclusions</h3><p>D-dimer, lower extremity DVT, and simplified wells score ≥ 2 were relevant to higher risks of PE, which will help to improve clinicians’ understanding of PE secondary to AECOPD.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"86 ","pages":"Article 101122"},"PeriodicalIF":2.2,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141555677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interstitial pneumonia with auto-immune features (IPAF): Is a change of criteria necessary?","authors":"Raphael Borie,&nbsp;Joshua J Solomon","doi":"10.1016/j.resmer.2024.101120","DOIUrl":"10.1016/j.resmer.2024.101120","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"86 ","pages":"Article 101120"},"PeriodicalIF":2.3,"publicationDate":"2024-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141405396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influenza and pneumococcal vaccination in patients with COPD from 3 French cohorts: Insufficient coverage and associated factors","authors":"Chantal Raherison ,&nbsp;Bernard Aguilaniu ,&nbsp;Maeva Zysman ,&nbsp;Pierre-Régis Burgel ,&nbsp;David Hess ,&nbsp;El Hassane Ouaalaya ,&nbsp;Thi Chien Tran ,&nbsp;Nicolas Roche ,&nbsp;investigators from COLIBRI, Initiatives BPCO and PALOMB cohorts","doi":"10.1016/j.resmer.2024.101112","DOIUrl":"10.1016/j.resmer.2024.101112","url":null,"abstract":"<div><h3>Background</h3><p>Low vaccination rates against influenza and <em>Streptococcus (S.) pneumoniae</em> infections in COPD could impair outcomes. Understanding underlying factors could help improving implementation.</p></div><div><h3>Objectives</h3><p>To describe vaccination rates at inclusion in COPD cohorts and analyze associated factors.</p></div><div><h3>Methods</h3><p>Between 2012 and 2018, 5927 patients with sufficient data available were recruited in 3 French COPD cohorts (2566 in COLIBRI-COPD, 2653 in PALOMB and 708 in Initiatives BPCO). Data at inclusion were pooled to describe vaccination rates and analyze associated factors.</p></div><div><h3>Results</h3><p>Mean age was 66 years, 34 % were women, 35 % were current smokers, mean FEV1 was 58 % predicted, 22 % reported ≥2 exacerbations in the year prior to inclusion, mMRC dyspnea grade was ≥2 in 59 %, 52 % had cardiovascular comorbidities and 9 % a history of asthma. Vaccinations rates in the year prior to study entry were 34.4 % for influenza + <em>S. pneumoniae</em>, 17.5 % for influenza alone and 8.9 % for <em>S. pneumoniae</em> alone. In multivariate analyses, influenza vaccination rate was greater in older age, smoking status, low FEV1, exacerbation history, mMRC dyspnea&gt;2, asthma history, hypertension, diabetes mellitus, and the year of inclusion. SP vaccination was associated with type of practice of the respiratory physician, age, smoking status, FEV1, exacerbation history, dyspnea grade, asthma history and the year of inclusion.</p></div><div><h3>Conclusion</h3><p>Rates of vaccination against influenza and <em>S. pneumoniae</em> infection at inclusion in COPD cohorts remain insufficient and vaccination appears restricted to patients with specific features especially regarding severity and comorbidities, which is not consistent with current recommendations.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"86 ","pages":"Article 101112"},"PeriodicalIF":2.3,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141275542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FREnch National Cohort of neuroendocrine cell Hyperplasia of Infancy (FRENCHI): Long-term consequences and risk factors of low body mass index","authors":"Jean-Christophe Dubus ,&nbsp;Morgane Dervaux ,&nbsp;Caroline Thumerelle ,&nbsp;Ralph Epaud ,&nbsp;Alice Hadchouel ,&nbsp;Philippe Reix ,&nbsp;Laurence Weiss ,&nbsp;Julie Mazenq ,&nbsp;Nadia Nathan","doi":"10.1016/j.resmer.2024.101115","DOIUrl":"https://doi.org/10.1016/j.resmer.2024.101115","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"86 ","pages":"Article 101115"},"PeriodicalIF":2.3,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141264113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concomitant ALK translocation and EGFR C797S mutation as resistance mechanisms to osimertinib in an EGFR-mutant NSCLC patient","authors":"Elvire Pons-Tostivint ,&nbsp;Pauline Hulo ,&nbsp;Christine Sagan ,&nbsp;Thomas Papazyan ,&nbsp;Guillaume Herbreteau ,&nbsp;Marc Denis","doi":"10.1016/j.resmer.2024.101116","DOIUrl":"10.1016/j.resmer.2024.101116","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"86 ","pages":"Article 101116"},"PeriodicalIF":2.3,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590041224000321/pdfft?md5=08870a598861b1930503e0d17913b5eb&pid=1-s2.0-S2590041224000321-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141050831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-life evaluation of NIV to CPAP switch in patients with chronic respiratory failure. A case control study","authors":"Louise Mathieu ,&nbsp;Claudio Rabec ,&nbsp;Guillaume Beltramo ,&nbsp;Serge Aho ,&nbsp;Pierre Tankere ,&nbsp;Déborah Schenesse ,&nbsp;Jade Chorvoz ,&nbsp;Philippe Bonniaud ,&nbsp;Marjolaine Georges","doi":"10.1016/j.resmer.2024.101114","DOIUrl":"10.1016/j.resmer.2024.101114","url":null,"abstract":"<div><h3>Background</h3><p>Non-invasive ventilation (NIV) is a standard of care for hypercapnic chronic respiratory failure (CRF). Obstructive sleep apnea syndrome (OSA) frequently contributes to hypoventilation in CRF patients. CPAP improves hypercapnia in selected COPD and obese patients, like NIV. We aimed to describe the profile of patients switching from NIV to CPAP in a cohort of patients on long-term ventilation and to identify the factors associated with a successful switch.</p></div><div><h3>Methods</h3><p>In this case-control study, 88 consecutive patients who were candidates for a NIV-CPAP switch were compared with 266 controls among 394 ventilated patients treated at the Dijon University Hospital between 2015 and 2020. They followed a standardized protocol including a poly(somno)graphy recorded after NIV withdrawal for three nights. CPAP trial was performed if severe OSA was confirmed. Patients were checked for recurrent hypoventilation after 1 and 23[14–46] nights under CPAP.</p></div><div><h3>Results</h3><p>Patients were 53% males, median age 65 [56–74] years, and median BMI 34 [25–38.5] kg/m². Sixty four percent of patients were safely switched and remained on long-term CPAP. In multivariate analysis, the probability of a NIV-CPAP switch was correlated to older age (OR: 1.3 [1.01–1.06]), BMI (OR: 1.7 [1.03–1.12]), CRF etiology (OR for COPD: 20.37 [4.2–98,72], OR for obesity: 7.31 [1.58–33.74]), circumstances of NIV initiation (OR for acute exacerbation: 11.64 [2.03–66.62]), lower pressure support (OR: 0.90 [0.73–0.92]), lower baseline PaCO₂ (OR: 0.85 [0.80–0.91]) and lower compliance (OR: 0.76 [0.64–0.90]). Among 72 patients who went home under CPAP, pressure support level was the only factor associated with the outcome of the NIV-CPAP switch, even ^{after adjustment for BMI and age (}<em>^p</em> ⁼ ^0.01) with a non-linear correlation. Etiology of chronic respiratory failure, age, BMI, baseline PaCO₂, circumstances of NIV initiation, time under home NIV or NIV compliance were not predictive of the outcome of the NIV-CPAP switch.</p></div><div><h3>Conclusions</h3><p>A NIV-CPAP switch is possible in real life conditions in stable obese and COPD patients with underlying OSA.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"86 ","pages":"Article 101114"},"PeriodicalIF":2.3,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141039710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study design and rationale for IFCT- 2203 TAXIO: A study that aims to evaluate the effectiveness of a first-line chemotherapy regimen without etoposide, combined with durvalumab, for patients with extensive disease small cell lung cancer","authors":"Denis Moro-Sibilot ,&nbsp;Lionel Falchero ,&nbsp;Camille Ardin ,&nbsp;Ayoube Zouak ,&nbsp;Olivier Molinier ,&nbsp;Philippe Romand ,&nbsp;Olivier Leleu ,&nbsp;Karim Amrane ,&nbsp;Célia Berndt ,&nbsp;Alexandra Langlais ,&nbsp;Franck Morin ,&nbsp;Virginie Westeel","doi":"10.1016/j.resmer.2024.101113","DOIUrl":"https://doi.org/10.1016/j.resmer.2024.101113","url":null,"abstract":"<div><h3>Background</h3><p>Studies have shown improvement in overall survival with anti-PD1/PD-L1 molecules in combination with cisplatin/carboplatin and etoposide as a first-line treatment for Small Cell Lung Cancer (SCLC). However, first-line efficacy remains limited and well below that observed in Non-Small Cell Lung Cancer (NSCLC). Etoposide may have a detrimental effect on lymphocyte activation, which could explain the limited benefit of immunotherapy in the first line and the lack of benefit in the second line for patients previously exposed to high levels of etoposide.</p></div><div><h3>Methods</h3><p>We initiated a multicenter, single-arm, open-label phase II study of a chemotherapy regimen with durvalumab, combined with carboplatin and paclitaxel for extensive disease SCLC. Eligible patients will receive durvalumab plus carboplatin and paclitaxel every 3 weeks for up to 4 cycles, followed by durvalumab every 4 weeks until progression or unacceptable toxicity. A total of 67 patients will be enrolled in this study, with a 12-month enrollment period and 36-month follow-up. The primary endpoint is Overall Survival (OS) rate at 12 months. Secondary endpoints are best response rate, OS, OS at 24- and 36 months, progression free survival (PFS), duration of response, quality of life and safety.</p></div><div><h3>Results</h3><p>This study aims to establish the efficacy of durvalumab combined with carboplatin and paclitaxel in patients with extensive disease Small Cell Lung Cancer.</p></div><div><h3>Clinical trial registration</h3><p>EU CT: 2023-504670-38-00.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"86 ","pages":"Article 101113"},"PeriodicalIF":2.3,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590041224000291/pdfft?md5=d8c5dc78c4fb0e6d28783f42e2ca43cd&pid=1-s2.0-S2590041224000291-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141264112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}